Literature DB >> 27303925

What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder.

Gerard Sanacora1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27303925     DOI： 10.1001/jamapsychiatry.2016.0780

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN： 2168-622X            Impact factor:   21.596


× No keyword cloud information.
  6 in total

Review 1.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

Review 2.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

3.  Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Biol Psychiatry       Date:  2016-09-30       Impact factor: 13.382

4.  Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.

Authors:  Allie J Widman; Lori L McMahon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-12       Impact factor: 11.205

5.  Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.

Authors:  Lauren Lepow; David A Luckenbaugh; Lawrence Park; Ioline D Henter; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2016-11-22       Impact factor: 4.791

Review 6.  Experimental medication treatment approaches for depression.

Authors:  D F Ionescu; G I Papakostas
Journal:  Transl Psychiatry       Date:  2017-03-21       Impact factor: 6.222
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.